Xceed 'Hones in' on Breast, Colon Cancer; Plans to Launch First FDA-Cleared Assay in '10

CEO David Deems said that Xceed has decided to engage the FDA early in the development process because the agency's "thinking on these types of tests is evolving" and the company would like to "stay connected to whatever approach they are thinking of putting in place."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.